Showing results (231-240 of 401) with videos related to

Sort By:
Pageof 41
Journal for Immunotherapy of Cancer|June 9, 2023
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Bonnie Yates, Alina Dulau-Florea, et al.
Nature Communications|July 28, 2016
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticityElad Jacoby, Sang M Nguyen, Thomas J Fountaine, et al.
Journal for Immunotherapy of Cancer|November 28, 2020
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemiaGeorge Mo, Hao-Wei Wang, Aimee C Talleur, et al.
Blood Cells, Molecules & Diseases|September 22, 2007
Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patientsPeter Lang, Ingo Mueller, Johann Greil, et al.
Frontiers in Immunology|June 20, 2019
Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) CellsMelanie Bremm, Lisa-Marie Pfeffermann, Claudia Cappel, et al.
Blood Advances|February 3, 2026
Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphomaFabian Knörr, Martin Zimmermann, Peter Bader, et al.
The Journal of Clinical Investigation|January 30, 2019
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapyTori N Yamamoto, Ping-Hsien Lee, Suman K Vodnala, et al.
Lancet (London, England)|October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialDaniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Blood Advances|December 18, 2025
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemiaAlexandra Dreyzin, Bonnie Yates, Haneen N Shalabi, et al.
Pageof 41